Evidence map›Paper›PMID 36860136›Full record

ArticleJournal of diabetes investigation2023

Graft failure after allogeneic islet transplantation in a patient with type 1 diabetes and a high anti-glutamic acid decarboxylase antibody titer.

Noriko Kodani, Daisuke Chujo, Aiko Terakawa, Kyoji Ito, Fuyuki Inagaki, Nobuyuki Takemura, Shinichi Matsumoto, Tsuyoshi Tajima, Norio Ohmagari, Kumiko Ajima and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Noriko KodaniDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4443-1545
Daisuke ChujoDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.
Aiko TerakawaDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.
Kyoji ItoHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Fuyuki InagakiHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Nobuyuki TakemuraHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Shinichi MatsumotoDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.
Tsuyoshi TajimaDepartment of Diagnostic Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kumiko AjimaDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.
Tadashi TakakiDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.
Yzumi YamashitaDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.
Koya ShinoharaDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroshi KajioDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.
Takuya AwataDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.
Masayuki ShimodaDepartment of Pancreatic Islet cell Transplantation, National Center for Global Health and Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0338-0008
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic islet transplantation is a β-cell replacement therapy for people with insulin-deficient diabetes who have difficulty in glycemic control and suffer from frequent severe hypoglycemia. However, the number of islet transplantations carried out is still limited in Asia. We report a case of allogeneic islet transplantation in a 45-year-old Japanese man with type 1 diabetes. Although the islet transplantation was successfully carried out, graft loss was observed on the 18th day. Immunosuppressants were used in accordance with the protocol, and donor-specific anti-human leukocyte antigen antibodies were not detected. Autoimmunity relapse was also not observed. However, the patient had a high titer of anti-glutamic acid decarboxylase antibody from before the islet transplantation, and autoimmunity might thus have affected the β-cells in the transplanted islet. The evidence is still scarce to reach conclusions, and further data accumulation is required to enable proper patient selection before islet transplantation.

Indexed as

Diabetes Mellitus, Type 1Hematopoietic Stem Cell TransplantationIslets of Langerhans TransplantationAntibodiesGlutamate DecarboxylaseHumansMaleMiddle AgedAntibodiesGlutamate DecarboxylaseAutoimmunityIslet transplantationType 1 diabetes mellitus

Identifiers

PMID36860136
PMCPMC10119917
OpenAlexW4322758685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.